Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey
Open Access
- 5 June 2012
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (11), 1649-1656
- https://doi.org/10.1002/acr.21755
Abstract
Objective To quantify the incremental direct medical expenditure associated with rheumatoid arthritis (RA) in the US population from a payer's perspective. Methods A probability-weighted sample of adult respondents from the Medical Expenditure Panel Survey (2008) was used to identify a cohort of patients with RA and compared to a control cohort without RA. Annual expenditure outcomes, including total expenditure and subgroups related to pharmacy, office-based visits, emergency department visits, hospital inpatient stays, and residual expenditures were estimated. Differences between the RA and control cohort were adjusted for sociodemographic factors, employment status, insurance coverage, health behavior, and health status using a generalized linear model with log link and gamma distribution. Statistical inferences on difference in expenditures between RA and non-RA controls were based on nonparametric cluster bootstrapping using percentiles. Results The adjusted average annual total expenditure of the RA cohort in 2008 US dollars (USD) was $13,012 (95% confidence interval [95% CI] $1,737–$47,081), while that of the control cohort was $4,950 (95% CI $567–$17,425). The incremental total expenditure of the RA patients as compared to non-RA controls was $2,085 (95% CI $250–$7,822). RA patients also had a significantly higher pharmacy expenditure of $5,825 (95% CI $446–$30,998) that was on average $1,380 (95% CI $94–$7,492) higher as compared to the controls. The summated total incremental expenditure of all RA patients in the US was $22.3 billion (2008 USD). Conclusion RA exerts considerable incremental economic burden on US health care, which is primarily driven by the incremental pharmacy expenditure.This publication has 30 references indexed in Scilit:
- Cost‐effectiveness of biologic response modifiers compared to disease‐modifying antirheumatic drugs for rheumatoid arthritis: A systematic reviewArthritis Care & Research, 2010
- Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals Of The Rheumatic Diseases, 2010
- Out‐of‐pocket expenses and their burden in patients with rheumatoid arthritisArthritis Care & Research, 2009
- Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007Annals Of The Rheumatic Diseases, 2009
- Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997Arthritis & Rheumatism, 2007
- Use of biologics in rheumatoid arthritis: Where are we going?American Journal of Health-System Pharmacy, 2006
- Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritisArthritis & Rheumatism, 2005
- The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative studyAnnals Of The Rheumatic Diseases, 2004
- An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional declineArthritis & Rheumatism, 1999